An antibody developed by researchers works against a wide range of COVID-19 variants and related coronaviruses, including past, present and potentially future strains. A monoclonal antibody ...

Now, investigators have identified an antibody that is able to neutralize all currently known variants of SARS-CoV-2, as well as distant coronavirus relatives that have some similarities to SARS and ...

The efficacy and safety of intravenous Lu AG09222, a humanized monoclonal antibody directed against the PACAP ligand, for migraine prevention are unclear. In a phase 2, double-blind, randomized ...

A monoclonal antibody appears effective at neutralizing the numerous variants of SARS-CoV-2, as well as related viruses in animals that could pose a threat if they were to begin spreading in people.

While the world waits an effective coronavirus vaccine, Eli Lilly has started late-stage human testing an antibody drug as an alternative way to prevent viral transmission in high-risk locations.

The spike protein of SARS-CoV-2, the virus that causes COVID-19, enables the virus to enter human cells and is the primary target for the body's antibodies. Previous research has shown that ...

In a study of 12 participants, researchers at Beth Israel Deaconess Medical Center (BIDMC) have demonstrated that a cocktail of three broadly neutralizing antibodies (bNAb) successfully suppressed ...

Antivenom (often spelled “antivenin”) is an antibody product that can disable a particular venom’s toxins. If injected quickly after a bite or sting, the antibodies in antivenom neutralize the venom, ...

Instead of teaching the immune system to create antibodies to fight off a specific virus, the new vaccine would instead teach ...

Antibodies are proteins that circulate in the blood and protect against foreign antigenic substances such as bacteria, viruses, fungi, parasites, chemicals, or toxins. They are Y-shaped structures ...

Antibodies are secreted immunoglobulin molecules produced mainly by plasma cells. The antigen-binding site of the antibody has a unique structure that allows it to bind antigen in a highly ...

MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc. is pleased to announce that its innovative bispecific antibody, INV724, developed for the treatment of neuroblastoma, has been awarded both Rare ...